Author pages are created from data sourced from our academic publisher partnerships and public sources.
Percutaneous tricuspid valve therapies: the new frontier
Moderate-to-severe tricuspid regurgitation (TR) affects ∼1.6 million patients in the USA, of whom only 8000 undergo tricuspid surgery annually; this results in an extremely large number of untreated… Expand
Conventional surgery and transcatheter closure via surgical transapical approach for paravalvular leak repair in high-risk patients: results from a single-centre experience.
- M. Taramasso, F. Maisano, +15 authors O. Alfieri
- European heart journal cardiovascular Imaging
- 1 October 2014
OBJECTIVES Paravalvular leaks (PVL) occur in up to 17% of all surgically implanted prosthetic valves. Re-operation is associated with high morbidity and mortality. Transcatheter closure via a… Expand
Surgical treatment of paravalvular leak: Long-term results in a single-center experience (up to 14 years).
- M. Taramasso, F. Maisano, +7 authors O. Alfieri
- The Journal of thoracic and cardiovascular…
- 1 May 2015
OBJECTIVES The aim of this study is to report the long-term outcomes (median follow-up time, 7 years; range, 1 month to 14 years) of patients who underwent surgery for paravalvular leak in our… Expand
Thoracoscopic appendage exclusion with an atriclip device as a solo treatment for focal atrial tachycardia.
A 15-year-old boy with incessant drug-refractory atrial tachycardia was referred to our department for an ablation procedure. The tachycardia was diagnosed at 13 years of age during routine medical… Expand
Severe thrombocytopenia and its clinical impact after implant of the stentless Freedom Solo bioprosthesis.
- A. Pozzoli, Gijs E De Maat, H. Hillege, Jacob J A Boogaard, E. Natour, M. Mariani
- The Annals of thoracic surgery
- 1 November 2013
BACKGROUND This single-center study analyzed the occurrence of severe thrombocytopenia and its clinical effect after concomitant and isolated aortic valve replacement (AVR) with the stentless Freedom… Expand
A predictive model for early mortality after surgical treatment of heart valve or prosthesis infective endocarditis. The EndoSCORE.
- M. Di Mauro, G. A. Dato, +58 authors G. Nappi
- International journal of cardiology
- 15 August 2017
BACKGROUND The aim of this large retrospective study was to provide a logistic risk model along an additive score to predict early mortality after surgical treatment of patients with heart valve or… Expand
Mitral valve repair
Mitral regurgitation (MR) is the most common valvular heart disease in the Western world. The MR can be either organic (mainly degenerative in Western countries) or functional (secondary to left… Expand
Current challenges in interventional mitral valve treatment.
- M. Taramasso, Alessandro Candreva, +9 authors F. Maisano
- Journal of thoracic disease
- 18 May 2015
Transcatheter mitral valve therapies have emerged as an alternative option in high surgical risk or inoperable patients with severe and symptomatic mitral regurgitation (MR). As multiple technologies… Expand
Transcatheter mitral valve chord repair.
- V. Savić, A. Pozzoli, +9 authors M. Taramasso
- Annals of cardiothoracic surgery
- 16 October 2018
The field of mitral valve disease diagnosis and management is rapidly evolving. New understanding of pathophysiology and improvements in the adoption of sophisticated multimodality imaging modalities… Expand
First-in-Man Implantation of a Tricuspid Annular Remodeling Device for Functional Tricuspid Regurgitation.
- A. Latib, E. Agricola, +12 authors F. Maisano
- JACC. Cardiovascular interventions
- 1 November 2015
Tricuspid regurgitation (TR) is a common finding in patients with left-sided disease, and is associated with poor outcome and predicts poor survival, heart failure, and reduced functional capacity… Expand